| Safety and regulation
Pharmaceutical Commerce reported that the FDA sent warning letters to 30 telehealth firms over marketing that suggested compounded GLP-1 products were the same as approved ones.
Worth knowing: It shows how closely regulators are watching how compounded products are described. The Atlas does not rate or list any telehealth firm.
Related: Choosing an online service | Compounded versus brand-name medicines
Source: Pharmaceutical Commerce, March 4, 2026. News report on an FDA announcement of March 3, 2026; rules may have changed since Trade press, secondary source.